Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats

Wang, Lu-Wen; Wang, Likun; Chen, Hui; Cheng, Fan; Li, Xun; He, Can-Ming; Gong, Zuojiong

doi:10.3748/wjg.v18.i40.5709

Cited by 29 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18][19] However, the role of TSA on the ALF is still unknown. In this study, we observed how TSA affected on ALF rats' digestive system, including the liver, the small intestine, and the colon and further explored its potential mechanism.…”

Section: Introductionmentioning

confidence: 99%

Trichostatin A protects against intestinal injury in rats with acute liver failure

Zhang

Yang

et al. 2016

Journal of Surgical Research

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Trichostatin A protects against intestinal injury in rats with acute liver failure

Zhang

Yang

et al. 2016

Journal of Surgical Research

Self Cite

View full text Add to dashboard Cite

“…Drug-induced acute fatal liver injury is the leading cause of acute liver failure (ALF) in the developed countries [43–46], and ALF has a high mortality and the treatment is still quite challenging [43]. …”

Section: Ep Ameliorates Severe Acute Pancreatitis (Sap) and Attenuatementioning

confidence: 99%

“…Acute-on-Chronic liver failure (ACLF) rats have significantly increased serum endotoxin, TNF-α, HMGB1, IFN-gamma and IL-18, EP administration (40 mg/kg was intraperitoneally injected at 3 h, 6 h, 12 h, 24 h after the induction of ACLF, and samples were taken 48 h after the induction of ACLF) decreases all of these changes to protect against ACLF in rats [46]. …”

Section: Ep Ameliorates Severe Acute Pancreatitis (Sap) and Attenuatementioning

confidence: 99%

Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries

2016

View full text Add to dashboard Cite

Ethyl pyruvate (EP) is a simple derivative of pyruvic acid, which is an important endogenous metabolite that can scavenge reactive oxygen species (ROS). Treatment with EP is able to ameliorate systemic inflammation and multiple organ dysfunctions in multiple animal models, such as acute pancreatitis, alcoholic liver injury, acute respiratory distress syndrome (ARDS), acute viral myocarditis, acute kidney injury and sepsis. Recent studies have demonstrated that prolonged treatment with EP can ameliorate experimental ulcerative colitis and slow multiple tumor growth. It has become evident that EP has pharmacological anti-inflammatory effect to inhibit multiple early inflammatory cytokines and the late inflammatory cytokine HMGB1 release, and the anti-tumor activity is likely associated with its anti-inflammatory effect. EP has been tested in human volunteers and in a clinical trial of patients undergoing cardiac surgery in USA and shown to be safe at clinical relevant doses, even though EP fails to improve outcome of the heart surgery, EP is still a promising agent to treat patients with multiple inflammatory organ injuries and the other clinical trials are on the way. This review focuses on how EP is able to ameliorate multiple organ injuries and summarize recently published EP investigations. Graphical AbstractThe targets of the anti-inflammatory agent EP

show abstract

“…The potent antioxidant effects of EP have been shown in some studies [14]. EP is basically derived from pyruvic acid [15]. It has also been shown that this molecule improves organ dysfunction in some situations, such as sepsis [16], ileus [17], acute pancreatitis [18] and organ ischemia and hemorrhagic shock [19,20,21].…”

Section: Introductionmentioning

confidence: 99%

Potentially beneficial effects of ethyl-pyruvate on diabetic nephropathy: an experimental and ultrastructural study

Bahadır¹,

Yildirim²,

Baran³

et al. 2016

pjp

View full text Add to dashboard Cite

Oxidative stress is one of the main reasons of the diabetic nephropathy, which is a complication of the diabetes mellitus (DM). The aim of this study was to investigate the possible role of ethyl-pyruvate (EP) in streptozotocin-induced diabetic rats' kidney. Four groups (n = 8) male Wistar albino rats were used as follows: controls group rats were received only sodium citrate buffer solution by intraperitoneally (ip). EP group was given 50 mg/kg EP ip. DM group, diabetes formed by inducing streptozotocin. DM + EP group, received 50 mg/kg EP ip. All animals received daily treatment for 14 days, and at the end of the study, the kidneys were removed: the left kidney of the rats for malondialdehyde (MDA) analysis and the right kidney for histological examination. There was normal appearance of the kidney tissues in the control and the EP administered groups. In DM group, there was evident basement membrane thickening, enlargement of mesangial matrix; swelling in some tubular epithelial cells was noticeable. In DM + EP administered group, nearly control group appearance as well as relatively thickening in the glomerular basal membrane were detected. The antioxidant effect of ethyl-pyruvate improved the renal structures in DM + EP group.

show abstract

Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats

Cited by 29 publications

References 43 publications

Trichostatin A protects against intestinal injury in rats with acute liver failure

Trichostatin A protects against intestinal injury in rats with acute liver failure

Ethyl pyruvate is a novel anti-inflammatory agent to treat multiple inflammatory organ injuries

Potentially beneficial effects of ethyl-pyruvate on diabetic nephropathy: an experimental and ultrastructural study

Contact Info

Product

Resources

About